Ignite Creation Date:
2025-12-24 @ 4:21 PM
Ignite Modification Date:
2025-12-26 @ 1:54 PM
Study NCT ID:
NCT01142466
Status:
COMPLETED
Last Update Posted:
2014-02-27
First Post:
2010-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-12
Start Date Type:
None
Primary Completion Date:
2009-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-01
Completion Date Type:
ACTUAL
First Submit Date:
2010-06-10
First Submit QC Date:
None
Study First Post Date:
2010-06-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-04-07
Results First Submit QC Date:
None
Results First Post Date:
2011-06-10
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-01-26
Last Update Post Date:
2014-02-27
Last Update Post Date Type:
ESTIMATED